Comparative Pharmacology
Head-to-head clinical analysis: NYSTAFORM versus VANOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTAFORM versus VANOBID.
NYSTAFORM vs VANOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
None Documented
None Documented
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism.
Category C
Category C
Antifungal
Antifungal and Corticosteroid Combination